EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis

Akshita Gupta, Laurent Peyrin-Biroulet, Ashwin N Ananthakrishnan

Clinical Gastroenterology and Hepatology · 2024-03 · 22 (3) · 499-512.e6

DOI: 10.1016/j.cgh.2023.07.027 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-03. Verfasst von Akshita Gupta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Neoplasms, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institutes of Health, Crohn's and Colitis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: There are limited data on the safety of immunosuppressive therapy use in individuals with immune-mediated diseases with a history of malignancy, particularly with newer biologic and small-molecule treatments. METHODS: We performed a systematic search of PubMed and Embase databases to identify studies examining the impact of immunosuppressive therapies on cancer recurrence across several immune-mediated diseases. Studies were pooled together using random-effects meta-analysis and stratified by type of treatment. Primary outcome was occurrence of incident cancers, defined as new or recurrent. RESULTS: Our meta-analysis included 31 studies (17 inflammatory bowel disease, 14 rheumatoid arthritis, 2 psoriasis, and 1 ankylosing spondylitis) contributing 24,328 persons and 85,784 person-years (p-y) of follow-up evaluation. Rates of cancer recurrence were similar among individuals not on immunosuppression (IS) (1627 incident cancers, 43,765 p-y; 35 per 1000 p-y; 95% CI, 27-43), receiving an anti-tumor necrosis factor (571 incident cancers, 17,772 p-y; 32 per 1000 p-y; 95% CI, 25-38), immunomodulators (1104 incident cancers, 17,018 p-y; 46 per 1000 p-y; 95% CI, 31-61), combination immunosuppression (179 incident cancers, 2659 p-y; 56 per 1000 p-y; 95% CI, 31-81). Patients receiving ustekinumab (5 incident cancers, 213 p-y; 21 per 1000 p-y; 95% CI, 0-44) and vedolizumab (37 incident cancers, 1951 p-y; 16 per 1000 p-y; 95% CI, 5-26) had numerically lower rates of cancer. There were no studies on Janus kinase inhibitors. Stratification of studies by timing of immunosuppression initiation did not reveal a medication effect based on early (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsInflammatory Bowel DiseasesHumansImmunosuppressive AgentsImmunosuppression TherapyImmunologic FactorsUstekinumabRecurrence

Stichwörter der Autor:innen

CancerImmune-Mediated DiseasesImmunosuppressionRecurrence

Substanzen

Immunosuppressive AgentsImmunologic FactorsUstekinumab

Autor:innen und Institutionen

  • Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Department of Gastroenterology, Centre Hospitalier Régional Universitaire-Nancy, Nancy, France; University of Lorraine, Inserm, Nutrition-Genetics and Exposure to Environmental Risks, Nancy, France.
  • Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Department of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: aananthak…

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health
  • Crohn's and Colitis Foundation

Zitieren

APA

Gupta, A., Peyrin-Biroulet, L., & Ananthakrishnan, A. N. (2024). Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 22(3), 499-512.e6. https://doi.org/10.1016/j.cgh.2023.07.027

Vancouver

Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN. Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. 2024;22(3):499-512.e6. doi:10.1016/j.cgh.2023.07.027

BibTeX
@article{Gupta2024,
  author = {Gupta, Akshita and Peyrin-Biroulet, Laurent and Ananthakrishnan, Ashwin N},
  title = {Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  volume = {22},
  number = {3},
  pages = {499--512.e6},
  doi = {10.1016/j.cgh.2023.07.027}
}
Kostenlos starten →